TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01499069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium
Description: Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months
Study: NCT01613365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oropharyngeal and nasopharyngeal decontamination with placebo
Study: NCT00940030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical bowel preparation
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enema
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enema
Description: fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
Study: NCT03228420

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senza HF10 Therapy
Description: Senza 10kHz Spinal Cord Stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: CMM
Description: Conventional Medical Management
Study: NCT03157167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT01823354

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Scales
Description: Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Scales
Description: Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions
Description: Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing).

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions
Description: Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing).

Intervention type: OTHER
Group type: OTHER
Intervention: Medical consultation
Description: open questions

Intervention type: OTHER
Group type: OTHER
Intervention: Medical consultation
Description: open questions
Study: NCT01232231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological decolonization treatment
Description: Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
Study: NCT00794781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
Study: NCT03115047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection
Description: 0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine Injection
Description: 0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
Study: NCT04516369

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec
Description: Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
Study: NCT02611960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study: NCT03968042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: Intramuscular injection for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Intravenous injection for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of vitamin B1, B6, C, E and mecobalamine
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of vitamin B1, B6, C, E and mecobalamine
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of vitamin B1, B6, C, E and mecobalamine
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Study: NCT02611960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study: NCT02524093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Training
Description: Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Study: NCT01340547

Intervention type: DRUG
Group type: OTHER
Intervention: palifosfamide-tris
Description: palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
Study: NCT01722396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT03547505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-Pilot®
Description: Glide path preparation using R-Pilot® in reciprocating manner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProGlider®
Description: Glide path preparation using ProGlider® in a rotating manner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual preparation
Description: Glide path preparation using manual K-files numbered from 08 to 15.
Study: NCT03012893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound transverse scan
Description: Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
Study: NCT01253512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-18
Description: A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-18
Description: A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
Study: NCT03298113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.

Intervention type: DEVICE
Group type: OTHER
Intervention: IAD Hospital Standard Care
Description: Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
Study: NCT03618472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG
Description: Regular strength metformin (850 mg/tab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch based placebo manufatured to mimic Metformin 850 mg
Study: NCT03966716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Fixation
Description: Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
Study: NCT03669042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhotoFix
Description: PhotoFix Patch Implantation
Study: NCT01253512

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT01597622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10 mg/kg administered intravenously over 1 hour every 4 weeks
Study: NCT03588481

Intervention type: DEVICE
Intervention: DESyne X2
Description: Novolimus-eluting stent
Study: NCT05007093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: If intolerance occurs, the dose can be downregulated
Study: NCT01933711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT03310710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viabahn BX stent
Description: Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
Study: NCT03012893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic technique
Description: C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
Study: NCT03693950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-066
Description: BCD-066 will be administered once a week intravenously in a dose 1 µg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aranesp
Description: Aranesp will be administered once a week intravenously in a dose 1 µg/kg
Study: NCT03079427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
Study: NCT03749733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)
Description: Marketed Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)
Description: Investigational Medicinal Product
Study: NCT03082651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating run training load
Description: Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating run training load
Description: Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating footwear
Description: Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating footwear
Description: Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant training
Description: Runners will be assigned identical training sessions over a 7-day period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant training
Description: Runners will be assigned identical training sessions over a 7-day period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant footwear
Description: Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
Study: NCT01564329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Description: Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Description: Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
Study: NCT04028167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential FLOT followed by chemoradiation
Description: Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
Study: NCT03082651

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant footwear
Description: Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
Study: NCT02752334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
Study: NCT02528409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Medication currently approved for major depression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03971734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson 0.05mg
Description: Regadensoson 0.05mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.1mg
Description: Regadensoson 0.1mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.2mg
Description: Regadensoson 0.2mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.4mg
Description: Regadensoson 0.4mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 0.7mg
Description: Regadensoson 0.7mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 1.0mg
Description: Regadensoson 1.0mg administered prior to MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadensoson 1.4mg
Description: Regadensoson 1.4mg administered prior to MRI
Study: NCT04502706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0189
Description: GS-0189 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously.
Study: NCT00954603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 25-100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: 0.5-2 mg
Study: NCT03888534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib intravenous injection in combination with reduction chemotherapy.
Study: NCT01898234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revaclear
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helixone high flux
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Study: NCT02515643

Intervention type: OTHER
Intervention: Endothelial dysfunction
Description: One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method

Intervention type: OTHER
Intervention: Endothelial dysfunction
Description: One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method
Study: NCT01898234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xevonta
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helixone low flux
Description: Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other